Actinogen Medical Limited (ATGGF)

Market Cap	45.95M
Revenue (ttm)	6.63M
Net Income (ttm)	-8.70M
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0200
Previous Close	0.0200
Day's Range	0.0200 - 0.0200
52-Week Range	0.0150 - 0.0200
Beta	1.74
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 19, 2025

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medica...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: ATGGF

Financial Performance

In 2024, Actinogen Medical's revenue was 9.93 million, an increase of 103.18% compared to the previous year's 4.89 million. Losses were -13.04 million, 21.3% more than in 2023.

Financial numbers in AUD